NCT03501979 2025-08-29Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDUniversity of Alabama at BirminghamPhase 2 Terminated17 enrolled 16 charts
NCT03054363 2023-11-13Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerUniversity of Colorado, DenverPhase 1/2 Completed42 enrolled 16 charts